SB297006 is a selective antagonist of the CXCR2 receptor, a chemokine receptor involved in inflammatory responses. It is primarily used in research settings to study the role of CXCR2 in processes such as neutrophil migration, inflammation, and immune cell activation. Due to its ability to inhibit CXCR2-mediated signaling, SB297007 has been applied in preclinical models of inflammatory diseases, including arthritis, lung inflammation, and ischemia-reperfusion injury. It also serves as a tool compound in cancer research, where CXCR2 signaling contributes to tumor growth and angiogenesis. Its use helps elucidate pathways involved in disease progression and supports the development of targeted anti-inflammatory and anti-cancer therapies.